SCHEMBL1438809

SCHEMBL1438809

O=C(O)CCN1CCOC(c2ccc(OCCOCc3ccccc3)cc2)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.53
CNR2 P34972 1/20 0.46
EGFR P00533 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HTT P42858 2/20 0.43
S1PR3 Q99500 1/20 0.43
KDM4E B2RXH2 5/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
NPY1R P25929 1/20 0.41
LTA4H P09960 1/20 0.40
S1PR5 Q9H228 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439286 0.95 S1PR1 (0.57) S1PR1CNR2EGFRMEN1KMT2A
Trifluoroacetic Acid SCHEMBL12003622 0.95 S1PR1 (0.48) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1439168 0.91 EGFR (0.54) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1439363 0.91 S1PR1 (0.54) S1PR1CNR2EGFRMEN1KMT2A
Trifluoroacetic Acid SCHEMBL12003563 0.90 S1PR1 (0.52) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1438021 0.89 S1PR1 (0.42) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1437860 0.89 S1PR1 (0.61) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1438125 0.88 S1PR1 (0.69) S1PR1CNR2MEN1KMT2AS1PR3
SCHEMBL325063 0.88 CNR2 (0.55) S1PR1CNR2EGFRMEN1KMT2A
SCHEMBL1438800 0.88 S1PR1 (0.56) S1PR1CNR2MEN1KMT2AS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045441-B2 (Thio)morpholine derivatives as S1P modulators ABBVIE BAHAMAS LIMITED (BS) 2015-06-02 US claimed
EP-2473490-B1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS ABBVIE BAHAMAS LTD (BS) 2014-02-26 EP claimed
US-20120220552-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS ABBVIE BAHAMAS LIMITED (BS) 2012-08-30 US claimed
EP-2473490-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS Abbott Healthcare Products B.V. (NL) 2012-07-11 EP claimed
WO-2011023795-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2011-03-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220552-A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS S1PR3, S1PR1, S1PR2 S1PR1 2/4885CNR2 10/4885EGFR 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.